Title
Category
Credits
Event date
Cost
  • LivDerm
  • TME
  • 1.00 AAPA Category I CME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Pediatric patients with skin of color (SOC) face unique challenges in managing AD, including issues with disease associated sequelae. In fact, these patients are more likely to suffer from more severe AD cases. It has also been observed that patients with darker pigmented skin are more likely to develop hypo or hyperpigmentation at the affected sites of disease, and these effects often remain long after the symptoms have gone.
  • LivDerm
  • TME
  • 1.50 AMA PRA Category 1 Credit
  • 1.50 Participation
$0.00
The treatment of AD is a clinical challenge on a global level. Targeted immunomodulatory agents, based on recent advances in the understanding of the disease pathophysiology, represent additional options for long-term control.
  • CMHC
  • 1.25 ABIM MOC and AMA PRA Category 1 Credit
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit
  • 1.25 ANCC
  • 1.25 CDE
  • 1.25 Participation
$0.00
Anemia is a common comorbidity in patients with chronic kidney disease (CKD), and is associated with significant morbidity and impacts on quality of life. The complicated pathophysiology of the condition and the disadvantages associated with current treatments are some of the major barriers that clinicians face in reducing the burden of anemia in patients with CKD.
  • LivDerm
  • TME
  • 1.00 AAPA Category I CME
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Psoriasis is an immune-mediated disease that currently affects more than 8 million Americans and 125 million people worldwide according to the World Psoriasis Day consortium. Symptoms of this disease are characterized by inflammation, commonly presenting as raised plaques and scales on the skin resulting from an overactive immune system.
  • CMHC
  • 1.25 ABIM MOC and AMA PRA Category 1 Credit
  • 1.25 ACPE Pharmacy
  • 1.25 AMA PRA Category 1 Credit
  • 1.25 ANCC
  • 1.25 CDE
  • 1.25 Participation
$0.00
Lowering LDL-C effectively and safely is crucial to prevent and lower the risk of adverse cardiovascular events, however, LDL-C goal achievement remains suboptimal, including in high-risk and very high-risk patients. The landscape of LDL-C lowering therapy has significantly evolved, with new consensus statements, newer agents, as well as important evidence that may help address some of the current gaps. Additionally, there is residual risk beyond LDL-C, including elevated triglyceride levels and elevated Lp(a).
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 Participation
$0.00
Increased sodium intake is considered to be a leading risk factor for cardiovascular disease (CVD), Additionally, the impact of commonly-used medications with high sodium content contributes to this burden.  As such, it is important to address the risk of increased sodium intake in patients with CVD or at CVD risk, including in patients with sleep disorders, as well as practical strategies to minimize the impact of elevated sodium.
  • LivDerm
  • TME
  • 2.00 ACPE Pharmacy
  • 2.00 AMA PRA Category 1 Credit
  • 2.00 ANCC
  • 2.00 Participation
$0.00
Hidradenitis suppurativa has significant impacts on patients’ quality of life, however, it remains underdiagnosed, misdiagnosed, or incorrectly treated.  Until recently, there was a scarcity of evidence about long-term management strategies and no evidence-based consensus guidelines.  The updated North American guidelines, as well as the growing armamentarium of agents in advanced clinical development, provide additional guidance for optimizing diagnosis and treatment of HS patients.  However, questions still remain about how to best individualize therapy and work as a partner with patients
  • CMHC
  • 0.75 ACPE Pharmacy
  • 0.75 AMA PRA Category 1 Credit
  • 0.75 ANCC
  • 0.75 Participation
$0.00
Despite advances, there are significant gaps in the diagnosis and treatment of aortic stenosis (AS) in women. Transcatheter aortic valve replacement (TAVR) has emerged as a viable treatment option in this setting, having demonstrated increased efficacy and safety for the treatment of AS in women. This activity covers important updates in the screening, diagnosis, and risk stratification of women with AS, as well as practical considerations for TAVR.
  • CMHC
  • 19.25 ACPE Pharmacy
  • 19.25 AMA PRA Category 1 Credit
  • 19.25 ANCC
  • 19.25 CDE
  • 19.25 Participation
$0.00
The recordings from the 18th Annual meeting are now available. 
  • CMHC
  • 1.00 ACPE Pharmacy
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 ANCC
  • 1.00 CDE
  • 1.00 Participation
$0.00
This activity consists of a recorded presentation at the 18th annual CMHC Annual Congress held from October 18-21, 2023, in Boston, MA. The session, “Tackling the Disproportionate Burden of Resistant Hypertension in Black Adults: Perspectives & Advances,” was presented by Keith C. Ferdinand, MD, and Debbie Cohen, MD. Drs. Ferdinand and Cohen discussed:The strategies to overcome barriers to hypertension control and cardiovascular diseases.The definitions, current treatment, and emerging approaches for resistant hypertension.

Pages